Abstract:Background: Adefovir dipivoxil (ADV)-induced renal tubular dysfunction and hypophosphatemic osteomalacia (HO) have been given great consideration in the past few years. However, no standard guidance is available due to a lack of powerful evidence from appropriate long-term prospective case-control studies and variations in the definition of renal adverse events. The aim of this study is to clarify clinical features of ADV-related HO in Chinese chronic hepatitis B patients with long-term ADV treatment in Chinese and non-Chinese comparative case series. Methods: Retrieval of case reports was based on Pubmed, CNKI, Wan Fang and VIP databases using the key words adefovir dipivoxil, hypophosphatemia, osteomalacia and Fanconi syndrome. We divided patients into Chinese (C group) and Foreign (F group) groups according to their nationality. Comparisons involving demographics, clinical manifestations, tests, treatment and prognosis were conducted between the two groups. Results: Of the patients screened, 120 Chinese patients were identified in the C group, and 32 non-Chinese patients were identified in the F group. The average age of the C group was younger than that of the F group (51.89 years ±10.96 years versus 56.47 years ±11.36 years, t = - 2.084, P = 0.039). No significant difference was found in gender (male to female, 3.29:1 versus 3:1, χ 2 = 0.039, P = 0.844). Although there was no significant difference in the duration of ADV therapy before ostalgia onset, the C group tended to develop adverse events earlier, by 2-3 years, while the F group developed adverse events at 4-5 years (Z = - 1.517, P = 0.129). Prognosis was good after adjustment of the ADV dose and supplemental administration of phosphate and calcitriol. Time to resolution of tubular dysfunction was commenced at the first month, and Chinese patients were more prone to recover in the first 3 months than non-Chinese patients (91.3% of patients in the C group versus 56.3% in the F group, Z = - 3.013, P = 0.003). Conclusions: Sufficient attention is required for middle-aged males before and during exposure to long-term ADV therapy, regardless of nationality. The clinical picture, laboratory and radiograph alterations are important clues for those patients and are usually characterized by polyarthralgia, renal tubular dysfunction and mineralization defects. Implementation of an early renal tubular injury index is recommended for patients with higher risk, which would prevent further renal injury.

A Retrospective Analysis of Adverse Drug Reaction Caused by Adefovir Dipivoxil

Early Kidney Injury During Long-Term Adefovir Dipivoxil Therapy for Chronic Hepatitis B.

Clinical Analysis of 11 Cases of Adefovir Dipivoxil-induced Renal Hypophosphatemia and Osteomalacia

Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report

The clinical and pathological features of adefovir dipivoxil-related renal impairment

Analysis of 84 Cases of Adverse Reactions Induced by Voriconazole

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance

Renal Safety of Adefovir Dipivoxil for Two-Year Treatment in Chinese Patients with Chronic Hepatitis B

Nephrogenic Hypophosphatemic Osteomalacia During Adefovir Monotherapy for Chronic Hepatitis B Monoinfection.

Factors associated with the therapeutic effect of lamivudine-resistant chronic hepatitis B during adefovir dipivoxil therapy

Adefovir Dipivoxil Induced Hypophosphatemic Osteomalacia:Report of Two Cases

Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series

Fanconi's syndrome caused by adefovir dipivoxil:a case report and literature review

Osteomalacia Induced by Long-Term Low-Dose Adefovir Dipivoxil: Clinical Characteristics and Genetic Predictors

Biopsy-proven Nephrotoxicity Induced by Adefovir

Signal Detection and Analysis of Adverse Events Associated with Genvoya® Based the FAERS Database

Hypophosphataemic osteomalacia in patients on adefovir dipivoxil

910 A PROSPECTIVE, RANDOMIZED STUDY OF EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A VERSUS ADEFOVIR DIPIVOXIL IN TREATING LAMIVUDINE- RESISTANT HBeAg-POSITIVE CHB

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

Population Pharmacokinetics of Adefovir Dipivoxil Tablets in Healthy Chinese Volunteers

Hypophosphatemic Osteomalacia with Low Back Pain Caused by Long-Term Oral Adefovir Dipivoxil, Two Cases Report and Literatures Review